P

Assignee

ASANA BIOSCIENCES LLC

US35 patents

Top patents by PatentIndex Score

US9944637B2Apr 17, 2018

P2X3 and/or P2X2/3 compounds and methods

ASANA BIOSCIENCES LLC5 citations82
US9908879B2Mar 6, 2018

P2X3 and/or P2X2/3 compounds and methods

ASANA BIOSCIENCES LLC5 citations82
US9382277B2Jul 5, 2016

Pyrimido-pyridazinone compounds and methods of use thereof

ASANA BIOSCIENCES LLC8 citations82
US10174039B2Jan 8, 2019

P2X3 and/or P2X2/3 compounds and methods

ASANA BIOSCIENCES LLC4 citations81
US9499495B2Nov 22, 2016

Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways

ASANA BIOSCIENCES LLC4 citations80
US10316080B2Jun 11, 2019

Protein-polymer-drug conjugates

ASANA BIOSCIENCES LLC4 citations72
US11103491B2Aug 31, 2021

Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer

ASANA BIOSCIENCES LLC2 citations71
US10751332B2Aug 25, 2020

Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer

ASANA BIOSCIENCES LLC2 citations71
US10647720B2May 12, 2020

Pyrimido-pyridazinone compounds and methods of use thereof

ASANA BIOSCIENCES LLC1 citations71
US10590127B2Mar 17, 2020

P2X3 and/or P2X2/3 compounds and methods

ASANA BIOSCIENCES LLC1 citations71
US10544145B2Jan 28, 2020

P2X3 and/or P2X2/3 compounds and methods

ASANA BIOSCIENCES LLC1 citations71
US10316039B2Jun 11, 2019

P2X3 and/or P2X2/3 compounds and methods

ASANA BIOSCIENCES LLC2 citations71
US10188654B2Jan 29, 2019

Uses of pyrimido-pyridazinones to treat cancer

ASANA BIOSCIENCES LLC3 citations71
US11339169B2May 24, 2022

P2X3 and/or P2X2/3 compounds and methods

ASANA BIOSCIENCES LLC2 citations70
US10611768B2Apr 7, 2020

P2X3 and/or P2X2/3 compounds and methods

ASANA BIOSCIENCES LLC2 citations70
US10471051B2Nov 12, 2019

Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer

ASANA BIOSCIENCES LLC3 citations70
US10183944B2Jan 22, 2019

Pyrimido-pyridazinone compounds and methods of use thereof

ASANA BIOSCIENCES LLC1 citations70
US9896445B2Feb 20, 2018

Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer

ASANA BIOSCIENCES LLC3 citations70
US11685736B2Jun 27, 2023

P2X3 and/or P2X2/3 compounds and methods

ASANA BIOSCIENCES LLC0 citations61
US11434278B2Sep 6, 2022

Protein-polymer-drug conjugates

ASANA BIOSCIENCES LLC1 citations61
US9044482B2Jun 2, 2015

Use of aminoindane compounds in treating overactive bladder and interstitial cystitis

ASANA BIOSCIENCES LLC2 citations61
US12077543B2Sep 3, 2024

P2X3 and/or P2X2/3 compounds and methods

ASANA BIOSCIENCES LLC0 citations60
US11925629B2Mar 12, 2024

Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer

ASANA BIOSCIENCES LLC0 citations60
US10912779B2Feb 9, 2021

Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways

ASANA BIOSCIENCES LLC0 citations59
US9375423B2Jun 28, 2016

Use of aminoindane compounds in treating overactive bladder and interstitial cystitis

ASANA BIOSCIENCES LLC1 citations51
US9533981B2Jan 3, 2017

Pyridine derivatives

ASANA BIOSCIENCES LLC0 citations50
US9180115B2Nov 10, 2015

Cyclohexylamines

ASANA BIOSCIENCES LLC0 citations50
US9371316B2Jun 21, 2016

Pyridine derivatives

ASANA BIOSCIENCES LLC0 citations49
US9266873B2Feb 23, 2016

Pyridine derivatives

ASANA BIOSCIENCES LLC0 citations49
US9757382B2Sep 12, 2017

Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways

ASANA BIOSCIENCES LLC0 citations48
US9199975B2Dec 1, 2015

Biaryl imidazole derivatives for regulating CYP17

ASANA BIOSCIENCES LLC0 citations48
US9115092B2Aug 25, 2015

Substituted quinazoline and pyrido-pyrimidine derivatives

ASANA BIOSCIENCES LLC0 citations48
US10226468B2Mar 12, 2019

Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways

ASANA BIOSCIENCES LLC0 citations47
US9145411B2Sep 29, 2015

Substituted amino-pyrimidine derivatives

ASANA BIOSCIENCES LLC0 citations35
US10695296B2Jun 30, 2020

Formulations, methods, kit, and dosage forms for improved stability of an active pharmaceutical ingredient

ASANA BIOSCIENCES LLC0 citations32